Valerinna Yogibuana Swastika Putri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Valerinna Yogibuana Swastika Putri has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Anna Fuji Rahimah
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia , Dr. Saiful Anwar General Hospital, Malang, East Java, Indonesia
6 shared publications - Cholid Tri Tjahjono
Division of Cardiac Prevention and Rehabilitation, Department of Cardiology and Vascular Medicine, Universitas Brawijaya – Dr. Saiful Anwar Teaching Hospital, Malang, Indonesia 65111
5 shared publications - Heny Martini5 shared publications
- Wella Karolina
Dr. Saiful Anwar General Hospital, East Java Province
5 shared publications - Ardian Rizal
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia
4 shared publications - Indra Prasetya
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia; Department of Cardiology and Vascular Medicine, Dr. Saiful Anwar General Hospital, Malang, Indonesia
4 shared publications
Latest Publications
- Open Access
- 13 October 2026
- Published by Brawijaya University in Heart Science Journal
- Vol. 7 (4) , 48-54
Longitudinal changes in right ventricular-pulmonary arterial coupling after defect closure in adult congenital heart disease: The LET SHINE registry
Background: Right ventricular-pulmonary arterial (RV-PA) coupling reflects right ventricular adaptation to afterload and can be estimated non-invasively by echocardiography. Whether coupling recovery after defect closure in adult left-to-right shunt congenital heart disease (CHD) differs by lesion location, and whether baseline coupling predicts persistent pulmonary hypertension (PH), remains poorly defined in Southeast Asian populations. Objective: To evaluate longitudinal change in echocardiographic RV-PA coupling after defect closure, compare trajectories between pre-tricuspid (atrial septal defect) and post-tricuspid (ventricular septal defect and patent ductus arteriosus) lesions, and assess baseline coupling as a predictor of persistent PH at 12 months. Methods: This retrospective cohort study included 93 adults with left-to-right shunt CHD from the LET SHINE Registry who underwent defect closure and echocardiography at baseline (T0), 3 months (T1), and 12 months (T2), right heart catheterization is performed before the defect was closed. Six RV-PA coupling ratios (TAPSE/sPAP, TAPSE/PVAcT, TAPSE/TRV max, FAC/sPAP, FAC/PVAcT, FAC/TRV max) were compared across time, between lesion groups (Linear Mixed Model), and by ROC analysis for persistent PH (echocardiographic sPAP ≥35 mmHg at T2). Result: All six ratios improved significantly from T0 to T1 (p<0.001) and remained stable to T2. Pre-tricuspid lesions had lower baseline coupling but greater, more sustained improvement (group×time interaction p<0.001 for all ratios). Persistent PH occurred in 23/93 patients (24.7%). Baseline TAPSE/sPAP and FAC/sPAP discriminated persistent PH (AUC 0.780 and 0.786) comparably to invasive mPAP and PVR (AUC 0.805 and 0.800). Conclusion: RV-PA coupling improves substantially within 3 months after defect closure (all ratios, p<0,001), reflecting an acute fall in RV loading once the shunt is closed rather than slow structural remodelling, but follows a lesion-specific trajectory (group×time interaction p≤0,012; greater 12-month gains in pre-tricuspid than post-tricuspid lesions, Cohen's d 0,53-0,77), consistent with the differing reversibility of volume-overload (ASD) versus combined volume-pressure overload (VSD/PDA) remodelling. Baseline coupling ratios offer non-invasive predictive value for persistent PH (TAPSE/sPAP and FAC/sPAP AUC 0,780 dan 0,786) comparable to invasive hemodynamics (mPAP and PVR AUC 0,805 dan 0,800), because these ratios capture RV function relative to its afterload rather than contractility alone. Keyword : Closure Defect; Congenital Heart Disease; Pulmonary Hypertension; Retrospective Studies; Right Ventricular-Pulmonary Arterial Coupling.
- 13 October 2026
- Published by Brawijaya University in Heart Science Journal
- Vol. 7 (4) , 48-54
Open AccessLongitudinal changes in right ventricular-pulmonary arterial coupling after defect closure in adult congenital heart disease: The LET SHINE registry
Background: Right ventricular-pulmonary arterial (RV-PA) coupling reflects right ventricular adaptation to afterload and can be estimated non-invasively by echocardiography. Whether coupling recovery after defect closure in adult left-to-right shunt congenital heart disease (CHD) differs by lesion location, and whether baseline coupling predicts persistent pulmonary hypertension (PH), remains poorly defined in Southeast Asian populations. Objective: To evaluate longitudinal change in echocardiographic RV-PA coupling after defect closure, compare trajectories between pre-tricuspid (atrial septal defect) and post-tricuspid (ventricular septal defect and patent ductus arteriosus) lesions, and assess baseline coupling as a predictor of persistent PH at 12 months. Methods: This retrospective cohort study included 93 adults with left-to-right shunt CHD from the LET SHINE Registry who underwent defect closure and echocardiography at baseline (T0), 3 months (T1), and 12 months (T2), right heart catheterization is performed before the defect was closed. Six RV-PA coupling ratios (TAPSE/sPAP, TAPSE/PVAcT, TAPSE/TRV max, FAC/sPAP, FAC/PVAcT, FAC/TRV max) were compared across time, between lesion groups (Linear Mixed Model), and by ROC analysis for persistent PH (echocardiographic sPAP ≥35 mmHg at T2). Result: All six ratios improved significantly from T0 to T1 (p<0.001) and remained stable to T2. Pre-tricuspid lesions had lower baseline coupling but greater, more sustained improvement (group×time interaction p<0.001 for all ratios). Persistent PH occurred in 23/93 patients (24.7%). Baseline TAPSE/sPAP and FAC/sPAP discriminated persistent PH (AUC 0.780 and 0.786) comparably to invasive mPAP and PVR (AUC 0.805 and 0.800). Conclusion: RV-PA coupling improves substantially within 3 months after defect closure (all ratios, p<0,001), reflecting an acute fall in RV loading once the shunt is closed rather than slow structural remodelling, but follows a lesion-specific trajectory (group×time interaction p≤0,012; greater 12-month gains in pre-tricuspid than post-tricuspid lesions, Cohen's d 0,53-0,77), consistent with the differing reversibility of volume-overload (ASD) versus combined volume-pressure overload (VSD/PDA) remodelling. Baseline coupling ratios offer non-invasive predictive value for persistent PH (TAPSE/sPAP and FAC/sPAP AUC 0,780 dan 0,786) comparable to invasive hemodynamics (mPAP and PVR AUC 0,805 dan 0,800), because these ratios capture RV function relative to its afterload rather than contractility alone. Keyword : Closure Defect; Congenital Heart Disease; Pulmonary Hypertension; Retrospective Studies; Right Ventricular-Pulmonary Arterial Coupling.
- Open Access
- 13 October 2026
- Published by Brawijaya University in Heart Science Journal
- Vol. 7 (4) , 22-27
Effects of metformin and empagliflozin on runt- related transcription factor-2 (RUNX2) mRNA expression in vascular calcification of metabolic syndrome rats
Background: Vascular calcification (VC) is a severe vascular complication of metabolic syndrome (MetS), strongly correlated with increased cardiovascular morbidity and mortality. One of the most important regulator of osteoblastic differentiation, runt-related transcription factor-2 (RUNX2) has a crucial role in VC by promoting the transformation of vascular smooth muscle cells (VSMCs) toward an osteoblast-like phenotype. Objective: This study explored the effect of MetS on VC by raising RUNX2 mRNA expression and how metformin and empagliflozin affect RUNX2 mRNA expression in MetS-induced rats. Methods: Twenty Sprague-Dawley male rats were randomly separated into four groups: negative control (NC), MetS, MetS treated with metformin 500 mg/kgBW/day, and MetS treated with empagliflozin 30 mg/kgBW/day. MetS was induced by a high-fat high-sucrose diet and low-dose streptozotocin injection. RUNX2 mRNA expression was measured using RT-PCR and aortic tissue was stained using hematoxylin-eosin. Result: MetS induction resulted in visible microcalcification within the aortic wall and significantly increased RUNX2 mRNA expression compared with the NC group (mean ± SD: 38 ± 15, p = 0.01), indicating enhanced VC. Metformin markedly reduced RUNX2 mRNA expression (mean ± SD: 73 ± 7, p = 0.03), whereas empagliflozin showed a non-significant decrease (mean ± SD: 76 ± 23, p = 0.87). Conclusion: MetS induction can stimulate VC accompanied by increased RUNX2 mRNA expression in rats aortic tissue. Metformin and empagliflozin mitigate these changes, with metformin showing a more pronounced effect. This strengthens the importance of controlling MetS to reduce the risk of VC. Keyword : Empagliflozin; Metabolic Syndrome; Metformin; RUNX2; Vascular Calcification.
- 13 October 2026
- Published by Brawijaya University in Heart Science Journal
- Vol. 7 (4) , 22-27
Open AccessEffects of metformin and empagliflozin on runt- related transcription factor-2 (RUNX2) mRNA expression in vascular calcification of metabolic syndrome rats
Background: Vascular calcification (VC) is a severe vascular complication of metabolic syndrome (MetS), strongly correlated with increased cardiovascular morbidity and mortality. One of the most important regulator of osteoblastic differentiation, runt-related transcription factor-2 (RUNX2) has a crucial role in VC by promoting the transformation of vascular smooth muscle cells (VSMCs) toward an osteoblast-like phenotype. Objective: This study explored the effect of MetS on VC by raising RUNX2 mRNA expression and how metformin and empagliflozin affect RUNX2 mRNA expression in MetS-induced rats. Methods: Twenty Sprague-Dawley male rats were randomly separated into four groups: negative control (NC), MetS, MetS treated with metformin 500 mg/kgBW/day, and MetS treated with empagliflozin 30 mg/kgBW/day. MetS was induced by a high-fat high-sucrose diet and low-dose streptozotocin injection. RUNX2 mRNA expression was measured using RT-PCR and aortic tissue was stained using hematoxylin-eosin. Result: MetS induction resulted in visible microcalcification within the aortic wall and significantly increased RUNX2 mRNA expression compared with the NC group (mean ± SD: 38 ± 15, p = 0.01), indicating enhanced VC. Metformin markedly reduced RUNX2 mRNA expression (mean ± SD: 73 ± 7, p = 0.03), whereas empagliflozin showed a non-significant decrease (mean ± SD: 76 ± 23, p = 0.87). Conclusion: MetS induction can stimulate VC accompanied by increased RUNX2 mRNA expression in rats aortic tissue. Metformin and empagliflozin mitigate these changes, with metformin showing a more pronounced effect. This strengthens the importance of controlling MetS to reduce the risk of VC. Keyword : Empagliflozin; Metabolic Syndrome; Metformin; RUNX2; Vascular Calcification.
- Open Access
- 13 October 2026
- Published by Brawijaya University in Heart Science Journal
- Vol. 7 (4) , 69-76
In hospital major adverse cardiovascular events in acute heart failure: prognostic role of echocardiographic pulmonary hypertension probability
Background: Pulmonary hypertension secondary to left heart disease (PH-LHD) is predominant type of pulmonary hypertension observed in hospitalized acute heart failure (AHF) patients. Bedside echocardiography for AHF patients offers a pragmatic approach for assessing probability of pulmonary hypertension (PH); however, data correlating the probability of PH as determined by echocardiography to in hospital major adverse cardiovascular events (MACE) throughout hospitalization remain limited. Methods: This retrospective cohort study was undertaken at a single location, gathered data from the AHF registry at Saiful Anwar General Hospital in Malang, Indonesia, from January 2024 to December 2025. Adult patients admitted for acute heart failure who had transthoracic echocardiography (TTE) within 24 hours of arrival were incorporated into study. The probabilities of pulmonary hypertension, assessed via echocardiography, has been classified as low, moderate, or high in accordance with the 2022 ESC/ERS criteria. The principal outcome was in hospital MACE, characterized as in hospital mortality, cardiac arrest necessitating resuscitation, and/or cardiogenic shock needing medicinal or mechanical hemodynamic intervention. A hierarchical multivariate logistic regression analysis was conducted, controlling for age, sex, body mass index (BMI), Killip, left ventricular ejection fraction (LVEF), utilization of mineralocorticoid receptor antagonists (MRA), and angiotensin receptor-neprilysin inhibitor (ARNI) medication. Result: A total of 403 patients (median age 61 years; 56.6% male) were enrolled in study, with in-hospital MACE occurring in 124 patients (30.8%). The MACE rate increased in parallel with the increase in PH probability categories: 25.7% (Low), 30.4% (Moderate), and 48.0% (High; p < 0.001). Multivariate analysis demonstrated that elevated PH probability was an independent predictor of in hospital MACE across all three hierarchical models (Model 1: OR 2.91, 95% CI 1.67–5.07; Model 2: OR 2.84, 95% CI 1.63–4.95; Model 3: OR 2.97, 95% CI 1.66–5.32; all p < 0.001), even after full adjustment for LVEF and therapy. Killip class was an independent predictor in all models (OR 1.51–1.77). Therapy use: Beta Blocker (BB) (OR 0.54), MRA (OR 0.43), and ARNI (OR 0.19) each independently reduced the risk of MACE. The resultant model exhibited satisfactory discrimination (AUC 0.73, 95% CI 0.68–0.78) and robust calibration (Hosmer Lemeshow p = 0.41. Conclusion: A high probability of PH assessed using echocardiography can detect high-risk AHF and independently forecast MACE during hospitalization, irrespective of LVEF, clinical severity, and treatment modalities. These findings support the use of echocardiography-based PH probability for early bedside risk determination in hospitalized AHF patient. Keyword : Acute Heart Failure; Echocardiography; Left Heart Disease; Major Adverse Cardiovascular Events; Pulmonary Hypertension.
- 13 October 2026
- Published by Brawijaya University in Heart Science Journal
- Vol. 7 (4) , 69-76
Open AccessIn hospital major adverse cardiovascular events in acute heart failure: prognostic role of echocardiographic pulmonary hypertension probability
Background: Pulmonary hypertension secondary to left heart disease (PH-LHD) is predominant type of pulmonary hypertension observed in hospitalized acute heart failure (AHF) patients. Bedside echocardiography for AHF patients offers a pragmatic approach for assessing probability of pulmonary hypertension (PH); however, data correlating the probability of PH as determined by echocardiography to in hospital major adverse cardiovascular events (MACE) throughout hospitalization remain limited. Methods: This retrospective cohort study was undertaken at a single location, gathered data from the AHF registry at Saiful Anwar General Hospital in Malang, Indonesia, from January 2024 to December 2025. Adult patients admitted for acute heart failure who had transthoracic echocardiography (TTE) within 24 hours of arrival were incorporated into study. The probabilities of pulmonary hypertension, assessed via echocardiography, has been classified as low, moderate, or high in accordance with the 2022 ESC/ERS criteria. The principal outcome was in hospital MACE, characterized as in hospital mortality, cardiac arrest necessitating resuscitation, and/or cardiogenic shock needing medicinal or mechanical hemodynamic intervention. A hierarchical multivariate logistic regression analysis was conducted, controlling for age, sex, body mass index (BMI), Killip, left ventricular ejection fraction (LVEF), utilization of mineralocorticoid receptor antagonists (MRA), and angiotensin receptor-neprilysin inhibitor (ARNI) medication. Result: A total of 403 patients (median age 61 years; 56.6% male) were enrolled in study, with in-hospital MACE occurring in 124 patients (30.8%). The MACE rate increased in parallel with the increase in PH probability categories: 25.7% (Low), 30.4% (Moderate), and 48.0% (High; p < 0.001). Multivariate analysis demonstrated that elevated PH probability was an independent predictor of in hospital MACE across all three hierarchical models (Model 1: OR 2.91, 95% CI 1.67–5.07; Model 2: OR 2.84, 95% CI 1.63–4.95; Model 3: OR 2.97, 95% CI 1.66–5.32; all p < 0.001), even after full adjustment for LVEF and therapy. Killip class was an independent predictor in all models (OR 1.51–1.77). Therapy use: Beta Blocker (BB) (OR 0.54), MRA (OR 0.43), and ARNI (OR 0.19) each independently reduced the risk of MACE. The resultant model exhibited satisfactory discrimination (AUC 0.73, 95% CI 0.68–0.78) and robust calibration (Hosmer Lemeshow p = 0.41. Conclusion: A high probability of PH assessed using echocardiography can detect high-risk AHF and independently forecast MACE during hospitalization, irrespective of LVEF, clinical severity, and treatment modalities. These findings support the use of echocardiography-based PH probability for early bedside risk determination in hospitalized AHF patient. Keyword : Acute Heart Failure; Echocardiography; Left Heart Disease; Major Adverse Cardiovascular Events; Pulmonary Hypertension.
- Open Access
- 8 September 2026
- Published by Wolters Kluwer Health in Annals of Pediatric Cardiology
- Vol. 19 (5) , 475-489
Efficacy of catheter ablation for arrhythmia in adults with congenital heart disease: A meta-analysis of clinical outcomes
Background: Arrhythmias remain a major clinical challenge in adult congenital heart disease (aCHD), contributing significantly to increased hospitalization rates and cardiac complications, affecting over 50% of aCHD patients. Catheter ablation (CA) is regarded as a first-line therapeutic modality due to its potential for disease modification. However, concerns persist regarding its long-term efficacy and safety. Thus, a comprehensive evaluation of CA outcomes in this population is warranted. Methods: The outcomes of interest were the success rate, secondary ablation rate, complication rates, and recurrence of arrhythmias. Quality assessment was done using the Risk of Bias in Non-randomized Studies of Interventions tool, and meta-analysis was performed using RStudio. Results: A comprehensive search of seven databases yielded 15 articles for analysis, among which 10 were categorized as low-risk, four as moderate-risk, and one lacked information regarding bias. The single-arm meta-analysis, examining events per 100 observations, revealed a success rate of 85.37 (95% confidence interval [CI] =78.50, 92.24). Moreover, the secondary ablation rate was determined to be 29.29 (95% CI = 16.92, 41.66), while major complications occurred at a rate of 2.81 (95% CI = 0.89, 4.73) and minor complications at a rate of 5.29 (95% CI = 1.88, 8.70). The overall recurrence rate of arrhythmias was found to be 40.33 (95% CI = 28.37, 52.29), with specific rates for intra-atrial reentrant tachycardia at 20.33 (95% CI = 11.24, 29.43), atrial fibrillation at 14.25 (95% CI = 3.46, 25.05), and atrioventricular nodal reentrant tachycardia at 9.70 (95% CI = 0.00, 19.56). Lastly, the implantation rate of implantable cardioverter defibrilators (ICDs) was found to be 1.05 (95% CI = 0.12, 1.99). Conclusion: CA for arrhythmias in aCHD patients demonstrates high success rates with minimal procedural complications. However, the substantial recurrence rates highlight the need for ongoing monitoring and proactive strategies to optimize long-term outcomes.
- 8 September 2026
- Published by Wolters Kluwer Health in Annals of Pediatric Cardiology
- Vol. 19 (5) , 475-489
Open AccessEfficacy of catheter ablation for arrhythmia in adults with congenital heart disease: A meta-analysis of clinical outcomes
Background: Arrhythmias remain a major clinical challenge in adult congenital heart disease (aCHD), contributing significantly to increased hospitalization rates and cardiac complications, affecting over 50% of aCHD patients. Catheter ablation (CA) is regarded as a first-line therapeutic modality due to its potential for disease modification. However, concerns persist regarding its long-term efficacy and safety. Thus, a comprehensive evaluation of CA outcomes in this population is warranted. Methods: The outcomes of interest were the success rate, secondary ablation rate, complication rates, and recurrence of arrhythmias. Quality assessment was done using the Risk of Bias in Non-randomized Studies of Interventions tool, and meta-analysis was performed using RStudio. Results: A comprehensive search of seven databases yielded 15 articles for analysis, among which 10 were categorized as low-risk, four as moderate-risk, and one lacked information regarding bias. The single-arm meta-analysis, examining events per 100 observations, revealed a success rate of 85.37 (95% confidence interval [CI] =78.50, 92.24). Moreover, the secondary ablation rate was determined to be 29.29 (95% CI = 16.92, 41.66), while major complications occurred at a rate of 2.81 (95% CI = 0.89, 4.73) and minor complications at a rate of 5.29 (95% CI = 1.88, 8.70). The overall recurrence rate of arrhythmias was found to be 40.33 (95% CI = 28.37, 52.29), with specific rates for intra-atrial reentrant tachycardia at 20.33 (95% CI = 11.24, 29.43), atrial fibrillation at 14.25 (95% CI = 3.46, 25.05), and atrioventricular nodal reentrant tachycardia at 9.70 (95% CI = 0.00, 19.56). Lastly, the implantation rate of implantable cardioverter defibrilators (ICDs) was found to be 1.05 (95% CI = 0.12, 1.99). Conclusion: CA for arrhythmias in aCHD patients demonstrates high success rates with minimal procedural complications. However, the substantial recurrence rates highlight the need for ongoing monitoring and proactive strategies to optimize long-term outcomes.
- 13 July 2026
- Published by Brawijaya University in Heart Science Journal
- Vol. 7 (3) , 86-89
Atrial septal defect with pulmonary arterial hypertension in pregnancy : A case series
Background: Congenital heart disease (CHD) ranked among the most frequently encountered structural abnormalities in humans. Acyanotic congenital heart disease (CHD) persists as a global issue, with atrial septal defect (ASD) constituting the second most prevalent form, accounting for around 10% of all CHD cases and occurring more frequently in females than in males. Pregnancy physiologically modifies the cardiovascular system and may exacerbate the clinical condition of people with atrial septal defect and pulmonary hypertension, potentially resulting in heart failure. Case Presentations: We documented five examples of pregnant patients with ASD and pulmonary hypertension (PH). Two patients had established medical records and attended regular follow-up, one of whom underwent ASD closure. All patients had dilation of the right atrium and ventricle, with two individuals presenting right ventricular (RV) systolic dysfunction. All patients exhibited normal left ventricular (LV) systolic function. Notwithstanding the oversight of a multidisciplinary heart team and intensive care management, one of our patients succumbed following cesarean section delivery. The patient exhibited diminished right ventricular systolic function, a bidirectional shunt lesion, a significant maximal pressure gradient, and lacked any documented cardiovascular or obstetric medical history, presenting with a poor mWHO classification. She experienced unresolved postoperative shock and bleeding. Conclusions: Managing PH secondary to CHD among pregnant patients presents significant challenges for multidisciplinary teams. Intensive perioperative care is essential to minimize mortality and morbidity in pregnant women with PH. Careful planning of optimal medical therapy, timing and delivery method, and post-natal approach is vital to improve outcomes. Keyword : Congenital Heart Disease; Heart Team; Pregnancy; Pulmonary Hypertension.
- 13 July 2026
- Published by Brawijaya University in Heart Science Journal
- Vol. 7 (3) , 86-89
Atrial septal defect with pulmonary arterial hypertension in pregnancy : A case series
Background: Congenital heart disease (CHD) ranked among the most frequently encountered structural abnormalities in humans. Acyanotic congenital heart disease (CHD) persists as a global issue, with atrial septal defect (ASD) constituting the second most prevalent form, accounting for around 10% of all CHD cases and occurring more frequently in females than in males. Pregnancy physiologically modifies the cardiovascular system and may exacerbate the clinical condition of people with atrial septal defect and pulmonary hypertension, potentially resulting in heart failure. Case Presentations: We documented five examples of pregnant patients with ASD and pulmonary hypertension (PH). Two patients had established medical records and attended regular follow-up, one of whom underwent ASD closure. All patients had dilation of the right atrium and ventricle, with two individuals presenting right ventricular (RV) systolic dysfunction. All patients exhibited normal left ventricular (LV) systolic function. Notwithstanding the oversight of a multidisciplinary heart team and intensive care management, one of our patients succumbed following cesarean section delivery. The patient exhibited diminished right ventricular systolic function, a bidirectional shunt lesion, a significant maximal pressure gradient, and lacked any documented cardiovascular or obstetric medical history, presenting with a poor mWHO classification. She experienced unresolved postoperative shock and bleeding. Conclusions: Managing PH secondary to CHD among pregnant patients presents significant challenges for multidisciplinary teams. Intensive perioperative care is essential to minimize mortality and morbidity in pregnant women with PH. Careful planning of optimal medical therapy, timing and delivery method, and post-natal approach is vital to improve outcomes. Keyword : Congenital Heart Disease; Heart Team; Pregnancy; Pulmonary Hypertension.
- Open Access
- 13 July 2026
- Published by Brawijaya University in Heart Science Journal
- Vol. 7 (3) , 105-109
To seal or to vent? Hemodynamic-guided decision-making in an older patient with borderline large secundum atrial septal defect and pulmonary hypertension
Background: Determining whether an atrial septal defect (ASD) should be closed in older patients who already have pulmonary hypertension may present a clinical dilemma. This is particularly true when pulmonary vascular resistance (PVR) approaches commonly used operability thresholds. Case Illustrations: A 59-year-old woman was referred to our center because of progressive exertional dyspnea and declining functional capacity. Echocardiography evaluation showed a large secundum ASD with a significant left-to-right shunt and right-sided chamber enlargement. Right heart catheterization revealed a mean pulmonary artery pressure of 46 mmHg and a pulmonary vascular resistance of 7.1 Wood units. Following oxygen test, PVR decreased to 3.4 Wood units and the Qp/Qs ratio increased from 1.5 to 2.65, suggesting preserved pulmonary vascular responsiveness. Based on these findings, transcatheter ASD closure without fenestration was performed successfully. The intervention was completed without complications, and early follow-up showed improvement in symptoms along with more favorable hemodynamic findings. Conclusions: This case highlights how comprehensive hemodynamic and physiological assessment, including dynamic vasoreactivity testing, can guide operability decisions in older patients with ASD and elevated PVR. Reassessment of pulmonary vascular responsiveness may refine risk stratification and support individualized management. Keyword : Atrial Septal Defect; Pulmonary Hypertension; Pulmonary Vascular Resistance; Transcatheter Closure; Vasoreactivity Testing.
- 13 July 2026
- Published by Brawijaya University in Heart Science Journal
- Vol. 7 (3) , 105-109
Open AccessTo seal or to vent? Hemodynamic-guided decision-making in an older patient with borderline large secundum atrial septal defect and pulmonary hypertension
Background: Determining whether an atrial septal defect (ASD) should be closed in older patients who already have pulmonary hypertension may present a clinical dilemma. This is particularly true when pulmonary vascular resistance (PVR) approaches commonly used operability thresholds. Case Illustrations: A 59-year-old woman was referred to our center because of progressive exertional dyspnea and declining functional capacity. Echocardiography evaluation showed a large secundum ASD with a significant left-to-right shunt and right-sided chamber enlargement. Right heart catheterization revealed a mean pulmonary artery pressure of 46 mmHg and a pulmonary vascular resistance of 7.1 Wood units. Following oxygen test, PVR decreased to 3.4 Wood units and the Qp/Qs ratio increased from 1.5 to 2.65, suggesting preserved pulmonary vascular responsiveness. Based on these findings, transcatheter ASD closure without fenestration was performed successfully. The intervention was completed without complications, and early follow-up showed improvement in symptoms along with more favorable hemodynamic findings. Conclusions: This case highlights how comprehensive hemodynamic and physiological assessment, including dynamic vasoreactivity testing, can guide operability decisions in older patients with ASD and elevated PVR. Reassessment of pulmonary vascular responsiveness may refine risk stratification and support individualized management. Keyword : Atrial Septal Defect; Pulmonary Hypertension; Pulmonary Vascular Resistance; Transcatheter Closure; Vasoreactivity Testing.
- 26 April 2026
- Published by Brawijaya University in Heart Science Journal
- Vol. 7 (2) , 13-19
Prognostic implications of pulmonary hypertension in heart failure preserved and reduced ejection fraction
Pulmonary hypertension (PH) attributable to left heart disease (PH associated with left heart disease, PH-LHD) is the most common type of PH. PH-LHD is an important indicator of elevated morbidity and mortality in individuals with heart failure, both heart failure with preserved and reduced ejection fraction despite receive adequate therapy. Literature was sourced from major scientific databases and studies relevant to symptoms, examinations, management, and prognostic implications of PH-LHD. Pathophysiologically, PH-LHD is a gradual process that begins with increased left-heart pressure (postcapillary component), which triggers a series of biological changes in the pulmonary vasculature (precapillary component). This process ultimately places an excessive burden on the right ventricle, resulting in right ventricular dysfunction and failure, which are the main determinants of prognosis. Symptoms of PH-LHD are usually characterized by disproportionate dyspnea that is not consistent with left ventricular ejection fraction and other comorbidities. Echocardiography can noninvasively assess the probability of pulmonary hypertension in heart failure patients. A definitive diagnosis of PH-LHD requires confirmation through right heart catheterization. The most important prognostic factors are not only determined by the degree of hemodynamic severity, but also depend heavily on the degree of right ventricular dysfunction and the status of right ventricle–pulmonary artery coupling. Management of PH-LHD is through optimization of basic Guideline-Directed Medical Therapy (GDMT) to reduce mortality and morbidity. Keyword : Heart Failure; Left Heart Disease; Pulmonary Hypertension.
- 26 April 2026
- Published by Brawijaya University in Heart Science Journal
- Vol. 7 (2) , 13-19
Prognostic implications of pulmonary hypertension in heart failure preserved and reduced ejection fraction
Pulmonary hypertension (PH) attributable to left heart disease (PH associated with left heart disease, PH-LHD) is the most common type of PH. PH-LHD is an important indicator of elevated morbidity and mortality in individuals with heart failure, both heart failure with preserved and reduced ejection fraction despite receive adequate therapy. Literature was sourced from major scientific databases and studies relevant to symptoms, examinations, management, and prognostic implications of PH-LHD. Pathophysiologically, PH-LHD is a gradual process that begins with increased left-heart pressure (postcapillary component), which triggers a series of biological changes in the pulmonary vasculature (precapillary component). This process ultimately places an excessive burden on the right ventricle, resulting in right ventricular dysfunction and failure, which are the main determinants of prognosis. Symptoms of PH-LHD are usually characterized by disproportionate dyspnea that is not consistent with left ventricular ejection fraction and other comorbidities. Echocardiography can noninvasively assess the probability of pulmonary hypertension in heart failure patients. A definitive diagnosis of PH-LHD requires confirmation through right heart catheterization. The most important prognostic factors are not only determined by the degree of hemodynamic severity, but also depend heavily on the degree of right ventricular dysfunction and the status of right ventricle–pulmonary artery coupling. Management of PH-LHD is through optimization of basic Guideline-Directed Medical Therapy (GDMT) to reduce mortality and morbidity. Keyword : Heart Failure; Left Heart Disease; Pulmonary Hypertension.
- Open Access
- 26 April 2026
- Published by Brawijaya University in Heart Science Journal
- Vol. 7 (2) , 29-35
A review of RUNX2 genetic interactions and their role in cardiovascular disease
Cardiovascular diseases (CVD) remain the leading cause of global mortality, with underlying factors such as genetics, environment, and lifestyle interacting in complex and multiple ways. Runt-related transcription factor 2 (RUNX2), traditionally associated with osteogenesis, has gained recognition for its critical role in cardiovascular health. RUNX2 contributes to vascular calcification (VC), endothelial dysfunction, and myocardial fibrosis, thereby accelerating CVD progression. Its expression is influenced by multiple upstream regulators relevant to vascular pathology, such as BMP2/SMAD, Wnt/β-catenin, and ERK signaling, along with epigenetic mechanisms and gene-environment interactions such as oxidative stress, hyperglycemia, and dyslipidemia. Genetic variants in RUNX2 and environmental variables including diet and physical inactivity, amplify its activation, worsening VC and cardiovascular risk. RUNX2 reduces endothelial nitric oxide bioavailability, enhances vascular inflammation, and activates profibrotic signaling in cardiac tissue, promoting vascular dysfunction and myocardial remodeling. Circulating RUNX2 levels and genetic variations exhibit potential as diagnostic and predictive indicators for cardiovascular disease. Severalpharmaceutical agents including metformin, empagliflozin, and statins, as well as natural substances such green tea polyphenols and green coffee extract, have demonstrated partial modulatory effects on RUNX2 activity. Moreover, genome-editing tools such as CRISPR-Cas9 present future opportunities for selective RUNX2 targeting. Comprehensive understanding of RUNX2 regulation and its interaction with genetic and environmental factors offers novel opportunities for personalized CVD prevention and treatment approaches through lifestyle modification, pharmacotherapy, and gene-based interventions in the future. Keyword : Cardiovascular Diseases; RUNX2; Therapeutic Targets; Vascular Calcification.
- 26 April 2026
- Published by Brawijaya University in Heart Science Journal
- Vol. 7 (2) , 29-35
Open AccessA review of RUNX2 genetic interactions and their role in cardiovascular disease
Cardiovascular diseases (CVD) remain the leading cause of global mortality, with underlying factors such as genetics, environment, and lifestyle interacting in complex and multiple ways. Runt-related transcription factor 2 (RUNX2), traditionally associated with osteogenesis, has gained recognition for its critical role in cardiovascular health. RUNX2 contributes to vascular calcification (VC), endothelial dysfunction, and myocardial fibrosis, thereby accelerating CVD progression. Its expression is influenced by multiple upstream regulators relevant to vascular pathology, such as BMP2/SMAD, Wnt/β-catenin, and ERK signaling, along with epigenetic mechanisms and gene-environment interactions such as oxidative stress, hyperglycemia, and dyslipidemia. Genetic variants in RUNX2 and environmental variables including diet and physical inactivity, amplify its activation, worsening VC and cardiovascular risk. RUNX2 reduces endothelial nitric oxide bioavailability, enhances vascular inflammation, and activates profibrotic signaling in cardiac tissue, promoting vascular dysfunction and myocardial remodeling. Circulating RUNX2 levels and genetic variations exhibit potential as diagnostic and predictive indicators for cardiovascular disease. Severalpharmaceutical agents including metformin, empagliflozin, and statins, as well as natural substances such green tea polyphenols and green coffee extract, have demonstrated partial modulatory effects on RUNX2 activity. Moreover, genome-editing tools such as CRISPR-Cas9 present future opportunities for selective RUNX2 targeting. Comprehensive understanding of RUNX2 regulation and its interaction with genetic and environmental factors offers novel opportunities for personalized CVD prevention and treatment approaches through lifestyle modification, pharmacotherapy, and gene-based interventions in the future. Keyword : Cardiovascular Diseases; RUNX2; Therapeutic Targets; Vascular Calcification.
- Open Access
- 1 March 2026
- Published by Wolters Kluwer Health in Annals of Pediatric Cardiology
- Vol. 19 (2) , 173-182
Accuracy of deep learning-based heart sound analysis as screening tool for congenital heart disease: A diagnostic meta-analysis
Background: With over 260,000 yearly mortality, 87% from low socio-economic countries, congenital heart disease (CHD) stands as a major global health crisis. Echocardiography, the current diagnostic standardized approach, often delays diagnosis due to interpretation variability and limited availability in low socioeconomic countries. Hence, exploring alternative screening approaches is crucial. The deep learning (DL) method coupled with heart sound analysis is a promising diagnostic approach for early CHD detection. Objectives: This study focuses on the innovation of DL-based heart sound analysis in enhancing the diagnosis of CHD patients. Methods: The outcomes of interest of the study were the sensitivity, specificity, and area under the curve (AUC) of various diagnostic tools and DL methods used in diagnosing CHD. Quality appraisal was done using Quality Assessment of Diagnostic Accuracy Studies 2, while the diagnostic meta-analysis used Stata MP 17. Results: A comprehensive search across seven databases yielded 19 articles for analysis. Among these, 13 were deemed low-risk and six unclear-risk of bias. The results were observed through meta-analysis with sensitivity at 91% (95% confidence interval [CI] = 0.85–0.94, P = 0.001), specificity at 92% (95% CI = 0.86–0.95, P = 0.001), and an AUC of 96% (95% CI = 0.94–0.98). Conclusions: The adoption of DL-based heart sound analysis for CHD diagnosis shows promise, demonstrating good diagnostic accuracy and potential as an adjunctive tool to support triage or pre-screening, although further validation is required before it can be considered alongside echocardiography.
- 1 March 2026
- Published by Wolters Kluwer Health in Annals of Pediatric Cardiology
- Vol. 19 (2) , 173-182
Open AccessAccuracy of deep learning-based heart sound analysis as screening tool for congenital heart disease: A diagnostic meta-analysis
Background: With over 260,000 yearly mortality, 87% from low socio-economic countries, congenital heart disease (CHD) stands as a major global health crisis. Echocardiography, the current diagnostic standardized approach, often delays diagnosis due to interpretation variability and limited availability in low socioeconomic countries. Hence, exploring alternative screening approaches is crucial. The deep learning (DL) method coupled with heart sound analysis is a promising diagnostic approach for early CHD detection. Objectives: This study focuses on the innovation of DL-based heart sound analysis in enhancing the diagnosis of CHD patients. Methods: The outcomes of interest of the study were the sensitivity, specificity, and area under the curve (AUC) of various diagnostic tools and DL methods used in diagnosing CHD. Quality appraisal was done using Quality Assessment of Diagnostic Accuracy Studies 2, while the diagnostic meta-analysis used Stata MP 17. Results: A comprehensive search across seven databases yielded 19 articles for analysis. Among these, 13 were deemed low-risk and six unclear-risk of bias. The results were observed through meta-analysis with sensitivity at 91% (95% confidence interval [CI] = 0.85–0.94, P = 0.001), specificity at 92% (95% CI = 0.86–0.95, P = 0.001), and an AUC of 96% (95% CI = 0.94–0.98). Conclusions: The adoption of DL-based heart sound analysis for CHD diagnosis shows promise, demonstrating good diagnostic accuracy and potential as an adjunctive tool to support triage or pre-screening, although further validation is required before it can be considered alongside echocardiography.
- 31 January 2026
- Published by Brawijaya University in Heart Science Journal
- Vol. 7 (1) , 63-67
The role of green tea and green coffee extract, empagliflozin and metformin treatment on FGF23 mRNA expression in calcified aorta tissue in metabolic syndrome model Sprague-Dawley rat
Background: Metabolic syndrome (MetS), encompassing dyslipidemia, glucose intolerance, hypertension, and central obesity, increases cardiovascular risk, including vascular calcification. Fibroblast growth factor 23 (FGF23), a bone-derived regulator of phosphate and vitamin D, is implicated in vascular calcification in kidney disease, but its role in MetS-related calcification is unclear. Objective: To determine if MetS promotes vascular calcification and alters aortic FGF23 mRNA expression in rats, and to assess effects of green tea/coffee extract, metformin, and empagliflozin on FGF23 mRNA modulation. Methods: Twenty-five Sprague-Dawley rats were divided into five groups: negative control, MetS (induced via high-fat/high-sucrose diet and streptozotocin), and three treatment groups (green tea/coffee extract, metformin 500mg/kg, empagliflozin 30mg/kg). Aortic calcification (hematoxylin-eosin staining) and FGF23 mRNA expression (qRT-PCR) were analyzed after 9 weeks. ANOVA with LSD post-hoc tests was used. Results: This study found MetS induction promoted vascular calcification. FGF23 mRNA expression increased in the MetS group compared to controls, though not statistically significant. All treatments reduced FGF23 mRNA levels modestly, but effects lacked statistical significance (p = 0.851–0.989), likely due to complex, tissue specific regulation of FGF23. Conclusion: Metabolic disturbances in MetS may prime vascular tissues for calcification without significantly altering local FGF23 mRNA expression. Interventions targeting oxidative stress, inflammation, or glucose metabolism could modulate FGF23-related pathways, warranting further investigation into the underlying signaling mechanisms. Keyword : Empagliflozin; FGF23; Metabolic Syndrome; Metformin; Vascular Calcification.
- 31 January 2026
- Published by Brawijaya University in Heart Science Journal
- Vol. 7 (1) , 63-67
The role of green tea and green coffee extract, empagliflozin and metformin treatment on FGF23 mRNA expression in calcified aorta tissue in metabolic syndrome model Sprague-Dawley rat
Background: Metabolic syndrome (MetS), encompassing dyslipidemia, glucose intolerance, hypertension, and central obesity, increases cardiovascular risk, including vascular calcification. Fibroblast growth factor 23 (FGF23), a bone-derived regulator of phosphate and vitamin D, is implicated in vascular calcification in kidney disease, but its role in MetS-related calcification is unclear. Objective: To determine if MetS promotes vascular calcification and alters aortic FGF23 mRNA expression in rats, and to assess effects of green tea/coffee extract, metformin, and empagliflozin on FGF23 mRNA modulation. Methods: Twenty-five Sprague-Dawley rats were divided into five groups: negative control, MetS (induced via high-fat/high-sucrose diet and streptozotocin), and three treatment groups (green tea/coffee extract, metformin 500mg/kg, empagliflozin 30mg/kg). Aortic calcification (hematoxylin-eosin staining) and FGF23 mRNA expression (qRT-PCR) were analyzed after 9 weeks. ANOVA with LSD post-hoc tests was used. Results: This study found MetS induction promoted vascular calcification. FGF23 mRNA expression increased in the MetS group compared to controls, though not statistically significant. All treatments reduced FGF23 mRNA levels modestly, but effects lacked statistical significance (p = 0.851–0.989), likely due to complex, tissue specific regulation of FGF23. Conclusion: Metabolic disturbances in MetS may prime vascular tissues for calcification without significantly altering local FGF23 mRNA expression. Interventions targeting oxidative stress, inflammation, or glucose metabolism could modulate FGF23-related pathways, warranting further investigation into the underlying signaling mechanisms. Keyword : Empagliflozin; FGF23; Metabolic Syndrome; Metformin; Vascular Calcification.